Is Zepbound available in the UK?

Not under that name. Zepbound is the US brand name for tirzepatide licensed for weight management. In the UK the same molecule, for the same weight-management use, is sold as Mounjaro, which the MHRA authorised for weight management on 8 November 2023. Anyone looking for "Zepbound" in the UK is looking for Mounjaro.

Can I get Wegovy or Mounjaro on the NHS?

Only if you meet the specific NICE criteria for that brand, which are narrower than the licensed indication. Wegovy requires referral into a specialist weight management service and a BMI of at least 35 with a comorbidity (or 30 to 34.9 meeting separate referral criteria), capped at 2 years of treatment. Mounjaro is being rolled out in phases by BMI and comorbidity count, with the criteria widening in stages through 2026 and into 2027. Meeting the drug's UK licence is not the same as meeting the NHS funding criteria.

Why is NHS access described as rationed rather than just restricted?

Because NICE's own committee papers say so: for tirzepatide, the manufacturer proposed criteria matching the full licence, and NICE's committee found that funding it for everyone the licence covers exceeded what it considers acceptable value for NHS money, so it approved a narrower group and a multi-year phased widening instead. That is a deliberate capacity and cost decision, not a description of who the drug works for.

How GLP-1 Access Actually Works in the United Kingdom

What this page establishes

The MHRA operates its own independent scrutiny of medicines applications, including under the International Recognition Procedure, which lets it consider a decision from a trusted regulator (such as the EMA or FDA) as supporting evidence without adopting it automatically: the MHRA retains sovereign authority to reject an application even where another regulator approved it.
The MHRA authorised Mounjaro (tirzepatide) for weight management in adults on 8 November 2023. There is no UK product marketed as Zepbound; tirzepatide is sold in the UK as Mounjaro for both the diabetes and weight-management indications.
The MHRA authorised a once-daily 25 mg oral semaglutide tablet under the Wegovy name for weight management on 11 June 2026. This is a separate product from Rybelsus, which is oral semaglutide licensed for type 2 diabetes at 3, 7 and 14 mg.
The MHRA authorised orforglipron (Foundayo) on 10 August 2026 for weight management and type 2 diabetes, the first authorisation for this molecule in Europe. NICE guidance on NHS use is due 18 November 2026; until then it is available only by private prescription.

Quick answers

Is Zepbound available in the UK?
Not under that name. Zepbound is the US brand name for tirzepatide licensed for weight management.
Read the full answer
In the UK the same molecule, for the same weight-management use, is sold as Mounjaro, which the MHRA authorised for weight management on 8 November 2023. Anyone looking for "Zepbound" in the UK is looking for Mounjaro.
Can I get Wegovy or Mounjaro on the NHS?
Only if you meet the specific NICE criteria for that brand, which are narrower than the licensed indication.
Read the full answer
Wegovy requires referral into a specialist weight management service and a BMI of at least 35 with a comorbidity (or 30 to 34.9 meeting separate referral criteria), capped at 2 years of treatment. Mounjaro is being rolled out in phases by BMI and comorbidity count, with the criteria widening in stages through 2026 and into 2027. Meeting the drug's UK licence is not the same as meeting the NHS funding criteria.
Why is NHS access described as rationed rather than just restricted?
Because NICE's own committee papers say so: for tirzepatide, the manufacturer proposed criteria matching the full licence, and NICE's committee found that funding it for everyone the licence covers exceeded what it considers acceptable…
Read the full answer
Because NICE's own committee papers say so: for tirzepatide, the manufacturer proposed criteria matching the full licence, and NICE's committee found that funding it for everyone the licence covers exceeded what it considers acceptable value for NHS money, so it approved a narrower group and a multi-year phased widening instead. That is a deliberate capacity and cost decision, not a description of who the drug works for.

Being licensed in the European Union does not make a medicine available in the United Kingdom. Since Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) grants UK marketing authorisations independently of the European Medicines Agency, so a brand's EU status is not evidence of its UK status. And being MHRA-licensed does not make a medicine free on the NHS: NHS funding for the weight-management brands runs through separate National Institute for Health and Care Excellence (NICE) technology appraisals, each with its own BMI and comorbidity thresholds, and NHS England has been rolling out funded access in phases rather than all at once.

Which of the nine brands are licensed in the UK

Seven of the nine brands hold a UK marketing authorisation under their US name: Ozempic, Wegovy, Rybelsus, Mounjaro, Saxenda, Victoza and Trulicity all have an active Summary of Product Characteristics (SmPC) on the electronic Medicines Compendium (EMC), which is the UK's public register of licensed product information.

Zepbound does not exist as a UK brand. Tirzepatide, the molecule sold in the United States as Mounjaro for diabetes and Zepbound for weight management, is sold in the UK under the single brand name Mounjaro for both indications. The MHRA authorised Mounjaro for weight management, as a new use of the existing licence, on 8 November 2023. There is no separate UK product called Zepbound, and a UK site or pharmacy using that name for tirzepatide is using a US brand name for a UK-licensed product that is not sold here under it.

Wegovy exists in the UK in two forms. The weekly injection has been licensed since 2021. A once-daily 25 mg oral semaglutide tablet, sold under the Wegovy name, was authorised by the MHRA on 11 June 2026. This is a different product from Rybelsus, which is oral semaglutide licensed for type 2 diabetes at lower doses (3, 7 and 14 mg).

Foundayo (orforglipron) is the most recent addition. The MHRA authorised it on 10 August 2026 for both weight management and type 2 diabetes, making the UK the first country in Europe to license it. At the time of writing it is not yet widely dispensed: Eli Lilly expected UK launch via private prescription and pharmacist-led Patient Group Direction services later in August 2026.

The naming trap this page exists to close US brand names and UK brand names do not always match one to one. Zepbound is a US name with no UK product behind it; the UK product for the same molecule and the same weight-management use is Mounjaro. Getting this backwards would send a UK reader looking for a product that pharmacies here do not stock.

NHS funding is a second, separate gate

A UK licence means a doctor may prescribe a medicine. It does not mean the NHS will pay for it. For the weight-management brands, NHS funding depends on a NICE technology appraisal (TA), and each one sets its own BMI and comorbidity criteria, which are consistently tighter than the licensed indication.

Wegovy (semaglutide) is covered by TA875, published March 2023. NICE recommends it only within a specialist weight management service (broadly tiers 3 and 4), for a maximum of two years, for adults with a BMI of at least 35 kg/m² and at least one weight-related comorbidity, or a BMI of 30 to 34.9 kg/m² who meet NICE's separate referral criteria for specialist obesity services. BMI thresholds are lowered by 2.5 kg/m² for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, reflecting NICE's guidance that obesity-related risk appears at a lower BMI in these groups.

Saxenda (liraglutide) is covered by TA664, published December 2020, and is more restrictive still: a tier 3 specialist multidisciplinary service, a BMI of at least 35 kg/m² (32.5 kg/m² with the same ethnicity adjustment), non-diabetic hyperglycaemia on specified blood test thresholds, and a high cardiovascular risk profile.

Mounjaro (tirzepatide) is covered by TA1026, published December 2024 and updated September 2025, and is the one NICE explicitly funded as a phased rollout because of the size of the eligible population. NHS England's interim commissioning guidance sets three cohorts over three years: eligible now, a BMI of 40 kg/m² or more with 4 or more of five listed weight-related conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes); from around June 2026, a BMI of 35 to 39.9 kg/m² with the same 4-or-more condition count; from around March 2027, a BMI of 40 kg/m² or more with 3 or more conditions. The same 2.5 kg/m² ethnicity adjustment applies throughout. Mounjaro can be prescribed in a specialist weight management service or, since a GP contract change from 1 April 2026, in primary care, though participation by individual GP practices is voluntary and locally funded, so availability still varies by area.

Ozempic, Rybelsus, Victoza and Trulicity are licensed for type 2 diabetes, not weight management, and are prescribed through the ordinary NHS diabetes care pathway rather than a dedicated weight-management technology appraisal. Prescribing an obesity-only brand off-label for weight loss, or a diabetes brand off-label in someone without diabetes, sits outside what any of these appraisals cover.

Foundayo has no NICE technology appraisal yet. NICE guidance on NHS use is due 18 November 2026; until then, it is a private-prescription-only medicine in the UK.

The queue is the point, not a side effect NICE's committee documents for tirzepatide record that the company proposed a BMI-30 threshold with one comorbidity, matching the drug's licence, and NICE rejected it as poor value for NHS money at that scale. The three-cohort rollout exists because NICE and NHS England judged that funding the full licensed population immediately was not affordable, not because of a supply shortage. A description of the criteria without the phasing dates would tell a reader they qualify today for access that, for most people in the middle cohort, does not open until around June 2026 at the earliest.

Private prescribing and what it costs

Anyone who does not meet the NHS criteria, or does not want to wait for their cohort, can be privately prescribed a licensed GLP-1 brand by a UK doctor or an independent prescriber. A private prescription still requires an appropriate clinical assessment; a prescriber operating without one, or supplying based on a questionnaire alone, is operating outside the standards the General Pharmaceutical Council and General Medical Council set for prescribing.

Neither the MHRA, NICE nor NHS England publishes a private retail price for these medicines, because that price is set commercially by individual pharmacies and prescribing services, not regulated as an NHS drug tariff price would be. This page does not quote a monthly cost figure, because the only current numbers available come from competing private pharmacy and telehealth marketing pages rather than a primary or regulatory source, and those figures change frequently and are not verifiable against an authoritative list. Anyone comparing private options should treat an advertised headline price as a starting point, not a total: separate charges for the prescriber consultation, follow-up, and delivery are common and are not part of the drug's own price.

MHRA safety position: unlicensed sourcing and falsified pens

The MHRA has an active safety record on GLP-1 products obtained outside a legitimate UK supply chain. In a drug safety update, it reported cases of falsified Ozempic and Saxenda pens found in the UK market: between January and October 2023 it seized 369 potentially falsified Ozempic pens, and confirmed cases where pens sold as semaglutide or liraglutide actually contained insulin. Several people who used falsified pens were hospitalised with hypoglycaemia, including seizures, because insulin and GLP-1 medicines lower blood glucose by entirely different mechanisms and are not interchangeable or dosed the same way.

The MHRA's guidance is to obtain these medicines only through a registered UK pharmacy against a genuine prescription, and to be alert to product packaging, batch numbers or pen appearance that does not match the SmPC and patient information leaflet on the EMC. Buying a GLP-1 medicine from an unregistered online seller, a source outside the UK supply chain, or anyone not asking for a genuine prescription, carries a demonstrated risk of receiving a falsified product rather than the medicine ordered.

The evidence, one row per claim

Claim	Tier	Source
The MHRA operates its own independent scrutiny of medicines applications, including under the International Recognition Procedure, which lets it consider a decision from a trusted regulator (such as the EMA or FDA) as supporting evidence without adopting it automatically: the MHRA retains sovereign authority to reject an application even where another regulator approved it.	established	MHRA / GOV.UK press notice, guidance on the International Recognition Procedure
The MHRA authorised Mounjaro (tirzepatide) for weight management in adults on 8 November 2023. There is no UK product marketed as Zepbound; tirzepatide is sold in the UK as Mounjaro for both the diabetes and weight-management indications.	established	MHRA / GOV.UK press notice, Mounjaro weight-management authorisation
The MHRA authorised a once-daily 25 mg oral semaglutide tablet under the Wegovy name for weight management on 11 June 2026. This is a separate product from Rybelsus, which is oral semaglutide licensed for type 2 diabetes at 3, 7 and 14 mg.	established	MHRA / GOV.UK press notice, oral semaglutide (Wegovy tablet) authorisation
The MHRA authorised orforglipron (Foundayo) on 10 August 2026 for weight management and type 2 diabetes, the first authorisation for this molecule in Europe. NICE guidance on NHS use is due 18 November 2026; until then it is available only by private prescription.	established	MHRA / GOV.UK press notice, orforglipron (Foundayo) authorisation
NICE TA875 (March 2023) recommends semaglutide (Wegovy) for weight management only within a specialist weight management service, for a maximum of 2 years, for a BMI of at least 35 kg/m2 with at least one weight-related comorbidity, or 30 to 34.9 kg/m2 meeting separate specialist-referral criteria, with a 2.5 kg/m2 lower threshold for specified minority ethnic groups.	established	NICE technology appraisal guidance TA875, Recommendations
NICE TA664 (December 2020) recommends liraglutide (Saxenda) for weight management only in a tier 3 specialist multidisciplinary service, for adults with a BMI of at least 35 kg/m2 (32.5 kg/m2 with ethnicity adjustment), non-diabetic hyperglycaemia on defined blood test thresholds, and high cardiovascular risk.	established	NICE technology appraisal guidance TA664, Recommendations
NICE TA1026 (December 2024, updated September 2025) recommends tirzepatide (Mounjaro) for weight management with a phased NHS rollout set by NHS England's interim commissioning guidance: eligible now at BMI 40+ with 4 or more of 5 listed comorbidities; from around June 2026 at BMI 35-39.9 with the same comorbidity count; from around March 2027 at BMI 40+ with 3 or more comorbidities. A 2.5 kg/m2 lower threshold applies for specified minority ethnic groups.	established	NICE technology appraisal guidance TA1026, Recommendations
Tirzepatide can be prescribed in primary care under the NHS GP contract from 1 April 2026, in addition to specialist weight management services, though individual GP practice participation is voluntary and locally funded.	established	NHS England, interim commissioning guidance for NICE TA1026 (tirzepatide)
Between January and October 2023 the MHRA seized 369 potentially falsified Ozempic pens in the UK and confirmed cases of falsified Ozempic and Saxenda pens containing insulin rather than the labelled GLP-1 medicine; several recipients were hospitalised with hypoglycaemia.	established	MHRA Drug Safety Update, Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products

Questions people ask

How much does private prescribing cost in the UK?

No regulator or NHS body publishes this figure, because private pricing is set commercially by individual pharmacies and prescribing services rather than fixed like an NHS drug tariff price. This page does not quote a number, because the only current figures available come from competing private pharmacy marketing pages rather than a primary source, and they are not stable enough to treat as established. Any private quote should be checked for what it excludes: prescriber consultation, follow-up, and delivery are often billed separately from the medicine itself.

Is it safe to buy these medicines from an online seller outside a UK pharmacy?

The MHRA has documented real harm from this. It identified falsified Ozempic and Saxenda pens circulating in the UK, some of which contained insulin instead of the labelled medicine, and several people who used them were hospitalised with hypoglycaemia. The MHRA's advice is to obtain these medicines only through a registered UK pharmacy against a genuine prescription.

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 9 sourced claims below the fold, each with the document it came from.

Sources consulted: MHRA / GOV.UK press notice, NICE technology appraisal guidance TA875, NICE technology appraisal guidance TA664, NICE technology appraisal guidance TA1026, NHS England and 1 more.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.